Cabot Corporation
NYSECBT has staged one of its sharpest recoveries in months, yet the Street is still not fully on board. The stock gained 7.1% on the week to close at $84.53, extending a 13.3% rally over the past month and lifting the year-to-date gain to 27.6%. Much of the fuel came from a strong Q2 earnings print on May 5, which drove a one-day jump of 8.6% and a five-day follow-through of 11.4%…
Snapshot as of 22 Jun 2026
CBT has staged one of its sharpest recoveries in months, yet the Street is still not fully on board. The stock gained 7.1% on the week to close at $84.53, extending a 13.3% rally over the past month and lifting the…
CBT reported Q2 fiscal 2026 results on May 5 that beat on every line — yet short sellers used the rally to add, not reduce. That tension sits at the heart of this week's setup. Cabot's headline numbers were clean.…
CBT heads into its Q2 2026 earnings release — due today — with options traders leaning unusually constructive for a specialty chemicals name facing genuine top-line headwinds. The put/call ratio has dropped sharply…
Cabot Corporation reports after the close today with short sellers the most active they have been in months — and options traders moving in the opposite direction. Short interest has climbed steadily and meaningfully…
Cabot Corporation heads into its May 4 Q2 results with short sellers adding positions at the fastest pace in months and options traders swinging decisively bullish — a direct conflict that makes this week's setup worth…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CBT — free to start on ORTEX.
Sign up for free →Open CBT on ORTEX